Generic manufacturer Mylan will not sell Dey L.P., its specialty pharmaceutical division. After a review, the company decided Dey L.P. would be positive for earnings through 2010.
There's a reason pharma lags on the programmatic adoption curve: It's a heavily regulated industry, and there are concerns around privacy.
Where are the discussions about applying proven behavior change models or the principles of adult learning and health literacy?
Such intense interest in health content is a rich opportunity to engage, inform, support, and motivate key customer constituencies.